Webinar: Targeted Degradation of the Enhancer Lysine Acetyltransferases CBP and p300

Discover how high-throughput Western blotting platforms are helping drive Targeted Protein Degradation (TPD) research programs. Dr. Christopher Ott, Assistant Professor at Harvard Medical School and Director of the Center for Molecular Therapeutics at Massachusetts General Hospital Cancer Center, will delve deeper into the development of a new chemical degrader p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (from ProteinSimple™, a Bio-Techne brand). Find out how Simple Western™ systems can be used to rapidly and reproducibly quantify protein knockdown following treatment with Degraders.